Maitland Labs of Central Florida, Orlando, FL
Is Maitland Labs of Central Florida registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.
Does Maitland Labs of Central Florida hold a Florida pharmacy license?
No license with this exact name and city was found in the Florida Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file covers pharmacy permits at Florida addresses. The file does list Maitland Labs of Central Florida, MAITLAND, a close but not exact match shown below.
Has Maitland Labs of Central Florida had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Aug 6, 2021) for Maitland Labs of Central Florida. State board actions: no Florida Board of Pharmacy action under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Maitland Labs of Central Florida
- Location
- Orlando, FL
- Type as FDA labels it
- 503A
- FDA’s note
- Out of business
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Aug 6, 2021
- FDA Data Dashboard inspections
- 2 inspections: 2 OAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 16 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Maitland Labs of Central Florida, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Aug 6, 2021 | Warning letter | Warning Letter (08/06/2021) | FDA copy (archived) |
| Feb 28, 2020 | Form 483 | 483 Issued 02/28/2020 | FDA copy (archived) |
| Jun 17, 2019 | Form 483 | 483 Issued 06/17/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Maitland Labs of Central Florida, Orlando, FL (FEI number 3013854204), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 28, 2020 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013854204 | 1119181 |
| Jun 17, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013854204 | 1093172 |
Form 483s FDA has published for this site
- Feb 28, 2020: Form 483 to Maitland Labs of Central Florida, published Mar 9, 2020. fda.gov
- Jun 17, 2019: Form 483 to Maitland Labs of Central Florida, published Mar 9, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 16 numbered observations in all, across 2 inspections ending Jun 17, 2019 to Feb 28, 2020. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 19, 2020 to Feb 28, 2020: 7 observations
- Firm on the cover
- Maitland Labs of Central Florida, 7972 Forest City Rd, Orlando, FL 32810-2907
- FEI number
- 3013854204
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically, according to your Pharmacy Technician, your firm is using non-sterile <Redacted B4> Disinfectant and non-sterile <Redacted B4> to clean and disinfect the Cleamoom and ISO <Redacted B4> 'Flow Hood. In addition, the sterile wipes utilized during cleaning can potentially shed particulates.
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
a. Your firm failed to follow your SOP #PRO-7.052 entitled, "Inspection Checks for Parenteral Products" Section 6.4.10 which states, <Redacted B4> ". This failure is evidenced by your firm not investigating when 93 vials of Nalbuphine HCL, l0mg/lmL, lot #20200108, compounded 1/8/20, exp: 1/30/21 <Redacted B4> vials produced) failed visual inspection for fibers. Your firm's Owner stated he believes the fibers were generated by the vial supplier, but no corrective or preventative actions have been taken by the firm.
b. On 1/8/20, during the <Redacted B4> of Nalbuphine HCL, 1 0mg/1 mL, lot #20200108 <Redacted B4> vials) the <Redacted B4> alerted the following alarms: exhaust rate too fast and door unsealed. ...
Observation 3
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
a. Your firm failed to follow the appropriate stability requirements for both temperature and humidity <Redacted B4> long term and <Redacted B4> accelerated) for the drug product, Nalbuphine HCL, l0mg/lmL, lot #20191111 R&D. As a result, your firm failed to have the stability data to support the over 12-month expiration date applied to the commercial Nalbuphine HCL, l0mg/lmL, lot #20200108, exp.: 1/30/21.
b. Your firm failed to perform the container closure integrity testing to ensure the adequacy of the container closure system to maintain a sterile barrier against potential contaminants.
C. Your firm failed to ensure that the Control Testing Laboratory's (CTL) potency method via <Redacted B4> is stability indicating and can detect impurities.
Repeated FDA-483 Observationji-om 6/17119
Observation 4
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically, your firm failed to conduct a smoke study under dynamic conditions within the ISO-5 <Redacted B4> low Hood <Redacted B4>). This hood was utilized for the production of Nalbuphine HCL, I0mg/lmL, lot #20200108.
Observation 5
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically,
C.
Your firm failed to ensure the sterility test method utilized by your firm's Control Testing Laboratory (CTL) is validated or verified under conditions of use utilizing your firm 's drug product, Nalbuphine HLC.
41 [( 21-) 4 d. <Redacted B4> used for incubating the product sample for endotoxin testing <Redacted B4> was located on top of a hand/equipment washing sink which causes vibrations and can potential lead to the dismption of any <Redacted B4> formed.
Rep eated FDA-483 Observationfi"om 6/17119
Observation 6
The labels of your outsourcing facility's drug products are deficient.
The label of your outsourcing facility's drug product does not include information required by section 503B(a)(l0)(A). Specifically, the following information is not found on your drug product label:
The established name of the drug, specifically the salt "HCl''
The strength, specifically the strength of the inactive ingredient, citric acid (anhydi·ous), is inconect: 0.063% vs. 0.63%
The dosage form •
The storage/handling instructions, specifically "Protect from light" and the storage conditions are not consistent with the batch record: 15-30°C, 59-86°F
Example of your drug product label that do not contain this information.
Nalbuphine HCl 10 mg/mL in 0.2% Saline
Repeated FDA-483 Observationji-om 6/17119
Observation 7
The container labels of your outsourcing facility's drug products are deficient.
The container of your outsourcing facility's drug product does not include information required by section 503B(a)(l0)(B). Specifically, your container does not include the following information:
The route of administration (i.e., intravenous)
• The storage/handling instructions, specifically "Protect from light" and the storage conditions are not consistent with the batch record (15-30°C, 59-86°F)
• The inactive ingredients, specifically: Sodium Hydroxide and Hydrochloric Acid, which are listed on the master batch record
• The complete name of the inactive ingredients: Sodium Citrate Dihydrate and Citric Acid Anhydrous
• "Inactive ingredient" appears on the label twice
Example of your drug product label that do not contain this information:
• Nalbuphine HCl 10 mg/mL in 0.2% Saline
Inspection Jun 4, 2019 to Jun 17, 2019: 9 observations
- Firm on the cover
- Maitland Labs of Central Florida, 7972 Forest City Rd, Orlando, FL 32810-2907
- FEI number
- 3013854204
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, your firm's SOP: ENV-4.018, Rev. 1, "Cleaning and Disinfection of the Facility is deficient as_ Section: 6.8-Formulation Lab and Section: 6.10-Cleanroom and Anteroom states <Redacted B4> shall be cleaned and disinfected at least <Redacted B4> to include walls, ceilings, benches and floors. In addition, no cleaning records were available for the Cleanroom (where <Redacted B4> for August 2018, December 2018 and February 2019. No cleaning records were available for the Formulation Lab (where drug products intended for terminal sterilization is conducted) for March 2018, April 2018, August 2018, September 2018, December 2018, January 2019 and February 2019.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring enviromnental conditions.
Specifically, your firm failed to follow SOP: ENV: 4.001, Rev. 2, "Enviromnental Monitoring Controls", Section: 7 .11-Enviromnental Monitoring of the Formulation Lab as it states, "monitoring of the formulation laboratory shall be completed <Redacted B4> Since registration as an outsourcing facility (March 2018), your firm has only conducted enviromnental monitoring (EM) two times (I 1/29/18 and 3/26/19) within the Formulation Laboratory ( cleamoom designated for terminally sterilized products). No EM was conducted during the filling operations for Epinephiine lmg/mL, 3mL vials, lot numbers: 4420190507A <Redacted B4> vials produced on 5/7/19), 20190507B <Redacted B4> vials produced on 6/5/19) and 20190507C <Redacted B4> vials produced on 6/6/19).
In addition, Section: 7.3-Cleamoom <Redacted B4> with no production activity) is deficient as it states to <Redacted B4> {providing unreliable environmental results). Your firm is not following the SOP as EM is being take <Redacted B4> and not on a <Redacted B4> basis when no production activities are taking place.
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Specifically, media fills utilizing <Redacted B4> are deficient as they were conducted outside of the cleanroom (as the firm stated would represent the worst-case scenario) but does not simulate conditions of actual production operations. In addition, no growth promotion testing has been conducted on the media (firm deliberately <Redacted B4>) and no environmental monitoring was conducted. The media fills also failed to document if all vials were incubated and if a 100% visual inspection was conducted.
Observation 4
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically,
a. Sterility testing has not been conducted by your firm's Contract Testing Laboratory (CTL), for the Epinephrine, 1mg/mL, 3mL vials, lot numbers: 20190507A ,Redacted B4> vials produced on 5/7/19), 20190507B <Redacted B4> vials produced on 6/5/19) and 20190507C <Redacted B4> vials produced on 6/6/19). In addition, your firm failed to ensure the sterility test method utilized by your firm's CTL is validated or verified under conditions of use utilizing your firm's drug product.
4 b. On 6/5/19, the <Redacted B4> (temperature: <Redacted B4> used for incubating the Epinephrine 1mg/mL, 3mL vials, lot # 20190507B for endotoxin testing by <Redacted B4> was observed located on top of a cabinet containing drawers which cause vibrations and can potential lead to the disruption of any <Redacted B4> formed.
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically, potency testing of the active ingredient has not been conducted by your firm's Contract Testing Laboratory (CTL), for the Epinephrine, lmg/mL, 3mL vials, lot numbers: 20190507A <Redacted B4> vials produced on 5/7/19), 20190507B <Redacted B4> vials produced on 6/5/19) and 20190507C <Redacted B4> vials produced on 6/6/19) by terminal sterilization. In addition, your firm failed to ensure the analytical test method utilized by your firm's CTL is validated or verified under conditions of use utilizing your firm's drug product.
Observation 6
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your firm failed to support your applied expiration date of 12 months through analytical data ensuring the Eginephrine, 1mg/mL, 3mL vials, lot numbers: 20190507A <Redacted B4> vials produced on 5/7/19), 20190507B <Redacted B4> vials produced on 6/5/19) and 20190507C <Redacted B4> vials produced on 6/6/19) will continue to meet established specifications for strength and purity throughout its specified shelf-life.
Observation 7
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, the ISO 5 LAFH within the Formulation Lab contained the HEPA filter gasket (black lining around the HEPA filter) which appeared to have small pieces missing. This ISO 5 LAFH was used to fill Epinephrine, lmg/mL, 3mL vials, lot numbers: 20190507A <Redacted B4> vials produced on 5/7/19), 20190507B <Redacted B4> vials produced on 6/5/19) and 20190507C <Redacted B4> vials produced on 6/6/19).
Observation 8
The labels of your outsourcing facility's drug products are deficient.
Specifically, the labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). The following information is not found on your drug product labels:
The address and phone number of the outsourcing facility;
The dosage form;
The statement "Office Use Only"
Examples of your drug product labels that do not contain this information:
Epinephrine Injection, USP I mg/mL
Observation 9
The container labels of your outsourcing facility's drug products are deficient.
Specifically, the containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B). Your containers do not include the following information:
• A list of active and inactive ingredients identified by established name and the quantity or proportion of each ingredient
Examples of your drug product container labels that do not contain this information:
• Epinephrine Injection, USP I mg/mL
State board of pharmacy records
No license with this exact name and city was found in the Florida Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file covers pharmacy permits at Florida addresses. Board file.
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Close but not exact board records
These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.
- License PH31682, Maitland Labs of Central Florida, MAITLAND, status Vol Relinquish: same name and state, different city.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.